FDA seeks more safety data for Injectafer
Executive Summary
Luitpold received a "not approvable" letter from FDA for the iron deficiency anemia drug Injectafer (ferric carboxymaltose), the firm reports March 12. The agency requests additional clinical trials to provide more data about a signal that led the Drug Safety and Risk Management Advisory Committee to vote 12-2 that Injectafer has a mortality disadvantage compared to oral iron (1"The Pink Sheet" Feb. 11, 2008, p. 28). Luitpold is working on new studies to support the application, CEO Mary Jane Helenek says
You may also be interested in...
Luitpold Citizen Petition May Handicap AMAG’s Ferumoxytol
A citizen petition filed by AMAG rival Luitpold stressing the dangers of intravenous iron therapy - an area with well-known hazards - seems designed to handicap AMAG's nanoparticle agent ferumoxytol, which bears a PDUFA date of Oct. 19
Injectafer Rejected For First-Line Use; Promising For Second-Line, Panel Says
Luitpold's Injectafer should be reserved for second-line use for treatment of iron deficiency anemia in postpartum patients and those with heavy uterine bleeding, FDA's Drug Safety and Risk Management Advisory Committee recommended Feb. 1
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.